Company intelligence / Profile preview
Skylark Bio
Cambridge, Massachusetts, United Statesskylarkbio.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Skylark Bio is developing innovative gene therapies aimed at addressing the underlying genetic causes of hearing impairment. The company is in preclinical or early clinical stages and has not yet reported late-stage clinical results or commercialized any products. Their approach seeks to restore natural communication by targeting sensory limitations through advanced genetic medicine.
- Therapeutic areas
- Neurology
- Modalities
- Gene therapyBiologic (as gene therapies are biologics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Skylark Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skylark Bio.